Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Biol Psychiatry. 2020 Mar 15;87(6):538-547. doi: 10.1016/j.biopsych.2019.07.034. Epub 2019 Aug 13.
Posttraumatic stress disorder, an area of large unmet medical needs, is characterized by persistence of fear memories and maladaptive stress responses. In rodents, elevation of the endocannabinoid anandamide due to inhibition of fatty acid amide hydrolase (FAAH) facilitates fear extinction and protects against the anxiogenic effects of stress. We recently reported that elevated anandamide levels in people homozygous for a loss-of-function FAAH mutation are associated with a similar phenotype, suggesting a translational validity of the preclinical findings.
In this double-blind, placebo-controlled experimental medicine study, healthy adults were randomized to an FAAH inhibitor (PF-04457845, 4 mg orally, once daily; n = 16) or placebo (n = 29) for 10 days. On days 9 and 10, participants completed a task battery assessing psychophysiological indices of fear learning, stress reactivity, and stress-induced affective responses.
FAAH inhibition produced a 10-fold increase in baseline anandamide. This was associated with potentiated recall of fear extinction memory when tested 24 hours after extinction training. FAAH inhibition also attenuated autonomic stress reactivity, assessed via electrodermal activity, and protected against stress-induced negative affect, measured via facial electromyography.
Our data provide preliminary human evidence that FAAH inhibition can improve the recall of fear extinction memories and attenuate the anxiogenic effects of stress, in a direct translation of rodent findings. The beneficial effects of FAAH inhibition on fear extinction, as well as stress- and affect-related behaviors, provide a strong rationale for developing this drug class as a treatment for posttraumatic stress disorder.
创伤后应激障碍是一个未得到充分满足医疗需求的领域,其特征是恐惧记忆的持续存在和适应不良的应激反应。在啮齿动物中,由于脂肪酸酰胺水解酶 (FAAH) 的抑制,内源性大麻素大麻酰胺的升高促进了恐惧的消除,并防止了应激的焦虑作用。我们最近报道,具有 FAAH 功能丧失突变纯合子的人升高的大麻酰胺水平与类似的表型相关,这表明了临床前发现的转化有效性。
在这项双盲、安慰剂对照的实验医学研究中,健康成年人被随机分为 FAAH 抑制剂(PF-04457845,口服 4 毫克,每日一次;n=16)或安慰剂(n=29)组,治疗 10 天。在第 9 天和第 10 天,参与者完成了一个任务组,评估了恐惧学习、应激反应和应激诱导的情感反应的心理生理指标。
FAAH 抑制导致基线大麻酰胺增加 10 倍。这与在消退训练后 24 小时测试时,恐惧消退记忆的增强回忆有关。FAAH 抑制还减弱了通过皮肤电活动评估的自主应激反应,并防止了应激诱导的负面情绪,通过面部肌电图测量。
我们的数据提供了初步的人类证据,表明 FAAH 抑制可以改善恐惧消退记忆的回忆,并减轻应激的焦虑作用,这是对啮齿动物发现的直接转化。FAAH 抑制对恐惧消退以及应激和情感相关行为的有益作用,为开发这种药物类别作为创伤后应激障碍的治疗方法提供了强有力的理由。